NAD+ (nicotinamide adenine dinucleotide) is not a peptide — it’s a coenzyme, and one of the most fundamental molecules in cellular biology. Present in every living cell, it shuttles electrons through the reactions that convert nutrients into usable energy, and doubles as the required substrate for entire families of signaling enzymes. Research interest exploded over the past two decades with a single consistent observation: NAD+ levels decline with age across essentially every tissue studied, and that decline tracks with many hallmarks of cellular aging.
This article summarizes the published research landscape: what NAD+ does, why its decline is a central topic in aging biology, and the practical considerations for working with NAD+ in a laboratory setting. As with everything in our Research Library, this is educational material about research-use-only material — nothing here describes or supports human use or supplementation.
What NAD+ Is
NAD+ operates in two fundamentally different modes, and the research literature is organized around that split:
Redox currency. In metabolism, NAD+ cycles continuously between its oxidized (NAD+) and reduced (NADH) forms, carrying electrons from glycolysis and the citric acid cycle into the mitochondrial electron transport chain. In this role it isn’t consumed — it’s recycled thousands of times, and the NAD+/NADH ratio is itself a key readout of a cell’s metabolic state.
Enzyme substrate. Separately, several enzyme families consume NAD+ outright, cleaving it to power their activity: sirtuins (SIRT1–7), PARPs (poly-ADP-ribose polymerases), and the CD38/CD157 hydrolases. This consumption is what makes NAD+ levels dynamic — and what makes the decline story mechanistically interesting rather than just correlational.
Mechanisms Under Investigation
1. Sirtuin signaling
Sirtuins are NAD+-dependent deacylases that regulate mitochondrial biogenesis, DNA repair, inflammation, and metabolic adaptation — the machinery most directly implicated in longevity research since the early work of Imai, Guarente, and colleagues (2000) established sirtuins as NAD+-dependent protein deacetylases. Because sirtuin activity is limited by NAD+ availability, falling NAD+ is hypothesized to functionally silence sirtuin-mediated maintenance programs in aging cells.
2. PARP activation and DNA damage
PARPs consume NAD+ heavily when activated by DNA damage. Chronic genotoxic stress — a feature of aging tissue — can drive persistent PARP activity that depletes the NAD+ pool, creating a proposed vicious cycle: more damage → more NAD+ consumption → less substrate for sirtuin-mediated repair. This competition between PARPs and sirtuins for a shared, shrinking substrate is one of the field’s organizing hypotheses.
3. CD38 and age-related decline
Work by Camacho-Pereira, Chini, and colleagues (2016) reported that the NAD+ hydrolase CD38 increases with age in mouse tissues and is a principal driver of age-related NAD+ decline in their models — shifting part of the field’s attention from reduced synthesis to increased consumption as the cause of the drop.
4. Restoration studies
A large preclinical literature examines restoring NAD+ levels in aged animals — via precursors (NMN, NR) or NAD+ itself — with reported effects on mitochondrial function, vascular health, and metabolic parameters in rodent models. Reviews by Verdin (2015) and by Rajman, Chwalek, and Sinclair (2018) catalog this work while noting the field’s central open question: how well rodent restoration findings translate, given that human trial results with precursors have so far been modest and mixed.
Reading the Literature Critically
- The decline is solid; the fixes are not. Age-related NAD+ decline is among the best-replicated observations in the field. What restoring it accomplishes — especially in humans — remains genuinely unsettled: human precursor trials have reliably raised blood NAD+ metabolite levels while producing inconsistent functional outcomes.
- Delivery and metabolism complexity. Extracellular NAD+ is not simply imported intact by most cells; it is largely degraded to precursors and rebuilt intracellularly. Experimental design in NAD+ research has to account for this, and it’s a common source of misinterpretation.
- Commercial gravity. The longevity-supplement industry has a large financial stake in this literature, several prominent researchers hold commercial interests, and marketing routinely outruns the data. Reading primary sources — not press coverage — matters more here than in most fields.
Laboratory Considerations
Verification. As a small molecule rather than a peptide, NAD+ identity and purity verification uses the same analytical logic: confirm the compound is what the label says at the purity stated. Every batch of NAD+ 500mg supplied by Full Scale Peptides is third-party tested, with the batch report published in our COA Library before purchase. See how to read a Certificate of Analysis for a walkthrough.
Stability. NAD+ is sensitive to heat, humidity, and pH extremes, degrading toward nicotinamide and related products under stress. Lyophilized material should be stored at −20°C, protected from light and moisture — general practices are covered in our storage and handling guide.
Reconstitution. In laboratory settings, researchers typically reconstitute with bacteriostatic water or buffers appropriate to the protocol, prepared fresh where the experimental design demands it given the molecule’s solution-stability profile.
Related compounds. NAD+ sits in our Growth & Longevity research category alongside MOTS-C, a mitochondrial-derived peptide studied in overlapping cellular-energy contexts.
Summary
NAD+ research runs on one hard observation — the molecule declines with age everywhere it’s measured — and a set of competing mechanistic stories about consumption by PARPs and CD38 versus synthesis, with sirtuin signaling as the downstream stake. The preclinical restoration literature is large and encouraging; the human data is early and honest readers say so. For laboratories working on metabolism and aging biology, material stability and verified purity are unusually consequential here, because NAD+ degrades into compounds that will quietly corrupt a dataset.
Browse NAD+ 500mg with its published batch COA, or explore the full catalog of third-party tested research compounds.
Research Use Only. All compounds referenced are intended solely for laboratory research and development purposes. Not for human or veterinary use. This article is educational material and does not describe, encourage, or support any use in humans or animals.
References
- Imai S, et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 2000.
- Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 2016.
- Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science, 2015.
- Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism, 2018.
- Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism, 2018.